EV Therapeutics develops off-the-shelf neoantigen-based immunotherapies from tumor-derived extracellular vesicles (EVs) and formulates proprietary therapeutic vaccines to enhance cancer treatment efficacy. self-described.

EV Therapeutics

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.

Alaunos Therapeutics, Inc.

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Metric
Company Name	EV Therapeutics	Alaunos Therapeutics, Inc.	Allogene Therapeutics, Inc.	Artiva Biotherapeutics, Inc. Common Stock
Symbol		TCRT	ALLO	ARTV
MSH ID	COM:EVTHERAPEUTICS	COM:ALAUNOS	COM:ALLOGENE	COM:ARTIVABIO
Market	PRIVATE	STOCKS	STOCKS	STOCKS
Sector	Healthcare & Health Services	Healthcare	Healthcare
Industry	Biotechnology	Biotechnology	Biotechnology
Country	US	US	US
Stage
Employee Count	1	1	232
Website	evtherapeutics.com	alaunos.com	allogene.com
LinkedIn			allogene-therapeutics
Founders

Metric
Market Cap	9.61M	498.99M	105.10M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	5K	95K	33.49M
Revenue (LTM)
Revenue (NTM)
Gross Profit	-4.80M	95K	33.49M
EBITDA	-34.27M	-287.05M	-29.11M
Operating Income	-34.27M	-314.49M	-30.67M
Net Income	-35.14M	-327.26M	-27.70M
EPS	-0.00	-2.09	-1.58
Diluted EPS	-0.00	-2.09	-1.58
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	-217	-68.24	1
Operating Profit Margin	-2.32K	-1.97K	-25.95
EBITDA Margin	-6.85K	-3.02K	-0.87
Net Profit Margin	-2.43K	-2.02K	-24.74
Return on Equity	-1.41	-0.53	0.18
Return on Assets	-1.87	-0.43	-0.34
Return on Capital Employed	-2.36	-0.44	-0.40

COM:EVTHERAPEUTICS

EV Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-14.38	-2.13	-6.48
P/B Ratio	37.65	1.21	-1.14
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	4.36K	7.08K	1.54K
EV Multiple	-0.43	-1.44	-8.29

Metric
Days Sales Outstanding			507.17
Days Payables Outstanding
Days Inventory Outstanding	0.00
Operating Cycle	243.33	8.49K
Cash Conversion Cycle	141.48	8.42K
Asset Turnover	0.00	0.00	0.01

Metric
Operating Cash Flow	-30.14M	-237.73M	-47.43M
Free Cash Flow	-30.34M	-239.25M	-50.69M
Cash Flow to Debt		-2.37	-1.80
Operating Cash Flow/Sales	-1.99K	-1.49K	-23.65
Free Cash Flow Yield	-0.86	-0.35	-0.12

Metric
Cash & Equivalents	6.06M	83.16M	53.50M
Accounts Receivable	3K		-510K
Inventory
Goodwill
Debt to Capitalization	0.08	0.17	-0.09
Debt to Assets	0.06	0.13	0.18
Current Ratio	2.75	12.58	6.35
Quick Ratio	5.16	12.80	6.35

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	228.47	365.40	2.61
R&D to Revenue	1.40K	1.42K	20.91
SG&A to Revenue	1.30K	405.65	6.04